Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating DepressionGlobeNewsWire • 05/17/23
Tonix Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsGlobeNewsWire • 05/08/23
Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney TransplantGlobeNewsWire • 05/04/23
A New Depression Drug Being Developed by Tonix May Side-Step Treatment-Limiting Effects of Nearly All Current Antidepressants in the USAccesswire • 04/27/23
Tonix Pharmaceuticals Announces Presentations of Pre-Clinical Data on TNX-1700 in Syngeneic Models of Colorectal and Gastric Cancer at the American Association for Cancer Research Annual Meeting 2023GlobeNewsWire • 04/19/23
Tonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft SurvivalGlobeNewsWire • 04/17/23
Tonix Pharmaceuticals Presents Data from its Vaccine Development Program at the World Vaccine CongressGlobeNewsWire • 04/06/23
Tonix Pharmaceuticals Announces Poster Presentations at the American Association for Cancer Research Annual Meeting 2023GlobeNewsWire • 04/05/23
Tonix Pharmaceuticals Presents Positive Efficacy and Safety Data from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 5th International Congress on Controversies in FibromyalgiaGlobeNewsWire • 03/30/23
Tonix Pharmaceuticals Announces Oral Presentations at the World Vaccine CongressGlobeNewsWire • 03/27/23
Tonix Pharmaceuticals exec presents data on Prader-Willi Syndrome drug at rare disease conferenceProactive Investors • 03/23/23
Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership SummitGlobeNewsWire • 03/23/23
Tonix Pharmaceuticals Announces Oral Presentation and Poster at the 5th International Congress on Controversies in FibromyalgiaGlobeNewsWire • 03/23/23
Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership SummitGlobeNewsWire • 03/16/23
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT' Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)GlobeNewsWire • 03/16/23
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsGlobeNewsWire • 03/13/23
Tonix Pharmaceuticals Announces Results from a Preclinical Study of Murine TNX-1700 Presented in a Poster at the Keystone Symposia, “Cancer Immunotherapy: Mechanisms of Response Versus Resistance”GlobeNewsWire • 03/07/23
Tonix Pharmaceuticals obtains exclusive license to develop fully human and murine anti-SARS-CoV-2 monoclonal antibodiesProactive Investors • 02/13/23
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal AntibodiesGlobeNewsWire • 02/13/23
Tonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Company's Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801)GlobeNewsWire • 02/09/23
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘PREVENTION' Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic MigraineursGlobeNewsWire • 02/06/23
